Editorial Videos

Rohit Tripathi, VP of Industry Strategy at RELEX, talks about who will actually pay for the phased tariff-driven cost increases.

Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not just domestic final assembly.

ADVI's Tyler Seville on how the IRA's drug pricing provisions are creating compliance burdens manufacturers can't meet without data they don't have.

ADVI's Tyler Seville on how 340B has become a financial liability for manufacturers while covered entities expand into wealthy suburban markets.

ADVI's Tyler Seville on how 340B grew from under $10 billion to over $100 billion annually — now larger than Medicaid and Medicare Part B.

Krieger Scientific's Joseph Morwald on why well-positioned pharma companies treat the FDA as a partner, invest in unbiased third-party oversight, and continuously raise the bar on compliance rather than treating it as a fixed threshold to clear.

Krieger Scientific's Joseph Morwald on why unverified AI-generated documentation in pharma is a complex issue with potentially significant consequences.

Krieger Scientific's Joseph Morwald explains how siloed departments, disconnected systems, and a lack of cross-functional accountability are creating the structural compliance gaps that FDA warning letters keep exposing.

Krieger Scientific's Joseph Morwald on why over-reliance on AI and under-reliance on human expertise is driving the surge in FDA warning letters.

John Stanford, executive director at Incubate, explains the COINS Act debate: should Treasury restrict US biotech investment in China, and what happens to American leadership if it does.

Incubate’s executive director John Stanford defines the three buckets of the US-China pharma challenge: API manufacturing, clinical trial competitiveness, and the complex ethics of licensing Chinese innovation.

John Stanford, executive director at Incubate, discusses how China's two decades of biotech investment are paying off.

TruTechnologies’ Dr. Richard Graham explains where he sees the actual issues that need to be addressed at FDA.

Susan Thomas, chief commercial officer at LucyRx, discusses how women in a certain age range are disproportionately impacted by cardiovascular risk.

Chief commercial officer Susan Thomas from LucyRx explains why coverage isn’t a one-size-fits all problem.

Dr. Richard Graham, chairman and co-founder of TruTechnologies, discusses the importance of global clinical trials while also being a center for these trials.

TruTechnologies’ chairman and co-founder Dr. Richard Graham explains why Australia and China are the main competitors for clinical trials.

LucyRx’s chief commercial officer Susan Thomas discusses the impact that only looking at immediate cost impact has on certain indications.

Gerren McHam, vice president of Government and External Affairs, API Innovation Center,argues that closing the gap between federal reshoring policy and manufacturer investment requires more than incentives.

Dr. Richard Graham from TruTechnologies details the likelihood that Project Trialblazer reduces trial times by 6-to-12 months.

Gerren McHam, vice president of Government and External Affairs, API Innovation Center, explains how geopolitical disruptions like the Strait of Hormuz situation have accelerated the organization's push to develop a national fragility index.

Susan Thomas, chief commercial officer at LucyRx, explains the areas where GLP-1 coverage still lacks.

Gerren McHam, vice president of Government and External Affairs, API Innovation Center, outlines why reshoring API manufacturing requires more than investment incentives.

Gerren McHam, vice president of Government and External Affairs, API Innovation Center, breaks down how China's new export control regulations expose drugmakers to operational risks that have yet to draw significant industry attention.

David Hung, CEO of Nuvation Bio, details the company’s ongoing trials for new drugs and new indications for existing molecules.

Nuvation’s CEO David Hung details the various cancer medications the company has on the market and in clinical trials.

David Hung, CEO of Nuvation Bio, explains the company’s current focus on US operations and how it utilizes partners for global impact.

Nuvation Bio’s CEO David Hung discusses the how Nuvation built a relatiohsip with Daichii Sankyo.